Revolution Medicines CEO Mark Goldsmith told the Financial Times that selling the company is 'not an area of high priority' even after daraxonrasib showed significantly better survival rates than chemotherapy in pancreatic cancer patients. The experimental drug targets the KRAS protein responsible for most pancreatic cancers, marking a breakthrough that was once considered scientifically impossible.

The company's stock has surged nearly 300% over the past year, lifting its market capitalization to approximately $33 billion. This follows an unsuccessful $32 billion takeover attempt by Merck in January. Despite fielding multiple acquisition inquiries from large pharmaceutical groups, Goldsmith emphasized the biotech is focused on advancing its treatment rather than seeking a buyer.

Industry consolidation has accelerated, with nearly $211 billion in pharmaceutical deals announced globally through early June. Revolution's clinically-proven asset makes it an attractive target as major drugmakers face patent expirations on blockbuster products. The FDA recently granted early access designation for daraxonrasib, allowing limited use in metastatic pancreatic cancer patients.

Trials are also testing the drug against lung and colorectal cancers. Former Senator Ben Sasse participated in the clinical trial, and only about 1% of patients discontinued treatment due to side effects like skin rash and fatigue. Goldsmith said the company feels the weight of responsibility that comes with changing cancer treatment paradigms.